Lanthanum hydroxide inhibits vascular calcification by regulating the HIF-1 pathway

Cell Biol Int. 2022 Aug;46(8):1275-1287. doi: 10.1002/cbin.11811. Epub 2022 May 11.

Abstract

The main reason for the high incidence of cardiovascular disease in chronic kidney disease (CKD) patients with vascular calcification (VC) is also the main cause of death in CKD patients. Lanthanum hydroxide (LH) has an inhibitory effect on VC in chronic renal failure; however, the mechanism of its inhibition is poorly defined. Here, we used network pharmacology analysis and found that hypoxia-inducible factor (HIF) is related to VC. In a CKD rat model induced by adenine combined with high phosphorus (1.2%), LH improved the survival rate and inhibited the occurrence and development of VC. In an in vitro study, we found that lanthanum chloride inhibited the occurrence of VC induced by high phosphorus and reduced the production of reactive oxygen species. This study thus revealed that LH can inhibit the occurrence and development of VC by inhibiting the activation of HIF-1.

Keywords: chronic kidney disease; hypoxia-inducible factor 1; lanthanum hydroxide; vascular calcification.

MeSH terms

  • Animals
  • Cardiovascular Diseases*
  • Lanthanum
  • Phosphorus / adverse effects
  • Rats
  • Renal Insufficiency, Chronic*
  • Vascular Calcification* / chemically induced
  • Vascular Calcification* / drug therapy
  • Vascular Calcification* / metabolism

Substances

  • Phosphorus
  • lanthanum hydroxide
  • Lanthanum